Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Set on La Gorce Island, a Miami Beach residence listed for $88 million—dubbed Okto—spans nearly 16,000 square feet with 260 ...

"Our alliance with Luminis Partners is an important component of our broader international focus to provide clients with strategic opportunities,” said Mark Van Lith, CEO of Guggenheim Securities. "We ...

Guggenheim initiated coverage of Sportradar (SRAD) with a Buy rating and $27 price target Discover the Best Stocks and Maximize Your Portfolio: ...

Wingstop (NASDAQ:WING – Get Free Report) was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating in ...

Guggenheim reaffirmed their buy rating on shares of CyberArk Software (NASDAQ:CYBR – Free Report) in a research note issued ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

LG and the Guggenheim New York proudly announce Ayoung Kim as the 2025 LG Guggenheim Award recipient. Kim is the third artist to be recognized as part of the LG Guggenheim Art and Technology ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

The artist is known for creating futuristic, interactive environments that reflect on contemporary geopolitical and ...

As previously reported, Guggenheim analyst Michael Schmidt initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price ...